183 related articles for article (PubMed ID: 15270663)
1. Current clinical management of gastrointestinal stromal tumors.
Tosoni A; Nicolardi L; Brandes AA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
3. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
4. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
6. [Gastrointestinal stromal tumors (GIST)].
Reichardt P; Pink D; Mrozek A; Lindner T; Hohenberger P
Z Gastroenterol; 2004 Apr; 42(4):327-31. PubMed ID: 15095124
[TBL] [Abstract][Full Text] [Related]
7. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
Bertucci F; Goncalves A; Monges G; Madroszyk A; Guiramand J; Moutardier V; Noguchi T; Dubreuil P; Sobol H
Oncol Rep; 2006 Jul; 16(1):97-101. PubMed ID: 16786129
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias.
Blay P; Astudillo A; Buesa JM; Campo E; Abad M; García-García J; Miquel R; Marco V; Sierra M; Losa R; Lacave A; Braña A; Balbín M; Freije JM
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4089-95. PubMed ID: 15217944
[TBL] [Abstract][Full Text] [Related]
10. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
de Jong FA; Verweij J
Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
[TBL] [Abstract][Full Text] [Related]
11. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
13. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Shiba K; Matsumoto T; Hirota S
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers.
Duensing S; Duensing A
Biochem Pharmacol; 2010 Sep; 80(5):575-83. PubMed ID: 20385106
[TBL] [Abstract][Full Text] [Related]
15. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
Sawaki A; Yamao K
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
Bümming P; Andersson J; Meis-Kindblom JM; Klingenstierna H; Engström K; Stierner U; Wängberg B; Jansson S; Ahlman H; Kindblom LG; Nilsson B
Br J Cancer; 2003 Aug; 89(3):460-4. PubMed ID: 12888812
[TBL] [Abstract][Full Text] [Related]
18. Imatinib: a targeted clinical drug development.
Capdeville R; Silberman S
Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
20. Current management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
[No Abstract] [Full Text] [Related]
[Next] [New Search]
